What is Lexicon Pharmaceuticals's revenue?

Lexicon Pharmaceuticals (LXRX) generated $69.6M in revenue over the trailing twelve months, up 123.1% year over year.

Is Lexicon Pharmaceuticals profitable?

Lexicon Pharmaceuticals is not currently profitable: it reported a net loss of $26.1M over the trailing twelve months, a -37.5% net margin.

What are Lexicon Pharmaceuticals's profit margins?

Gross margin is 99.5% and operating margin is -34.8%, with a -37.5% net margin.

What is Lexicon Pharmaceuticals's earnings per share?

Lexicon Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.07.

Where does Lexicon Pharmaceuticals's income statement data come from?

Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Lexicon Pharmaceuticals LXRX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$69.64M+123%	$49.8M+60.2%	$70.86M+1,255%	$58.43M+1,505%	$31.21M+1,251%
Total cost of revenue	$352K-42.8%	$274K-55.5%	$421K+24.6%	$482K+75.9%	$615K+430%
Gross profit	$69.29M+126%	$49.53M+62.6%	$70.44M+1,340%	$57.95M+1,621%	$30.6M+1,294%
Gross margin	99.5%+1.5pp	99.4%+1.4pp	99.4%+5.9pp	99.2%+6.7pp	98%+3.0pp
Research and development	$58.58M-31.4%	$61.12M-27.6%	$76.49M+5.4%	$83.52M+29.8%	$85.41M+39.5%
Selling, general and administrative	$34.94M-71.5%	$37.32M-73.9%	$60.82M-57.6%	$92.81M-31.8%	$122.65M-3.4%
Compensation and benefits	$12.55M+2.5%	$12.52M-7.3%	$11.22M-26.1%	$10.58M-35.0%	$12.24M-19.6%
Occupancy and equipment	$1.7M+13.3%	$1.6M+6.7%	$1.5M-6.3%	$1.5M-6.3%	$1.5M-6.3%
Depreciation and amortization	$555K-1.9%	$621K+16.3%	$628K+12.9%	$603K+3.8%	$566K-3.4%
Goodwill impairment	——	$0—	$0—	$0—	$0—
Other operating expenses	$8.09M-35.1%	$8.34M-46.5%	$10.17M-40.7%	$12.57M-23.7%	$12.47M-23.2%
Total costs & expenses	$93.87M-55.0%	$98.71M-56.7%	$137.73M-36.3%	$176.81M-11.9%	$208.68M+10.8%
Operating income	-$24.23M+86.3%	-$48.91M+75.2%	-$66.87M+68.3%	-$118.37M+39.9%	-$177.46M+4.6%
Operating margin	-34.8%+534pp	-98.2%+536pp	-94.4%+3,943pp	-202.6%+5,210pp	-568.6%+7,477pp
Interest expense	$6.84M-45.9%	$8.33M-35.5%	$9.77M-19.7%	$11.3M-11.7%	$12.63M+9.9%
Other income (expense), net	$6.23M-50.7%	$6.91M-43.8%	$8.46M-28.7%	$10.33M-9.6%	$12.63M+47.1%
Net investment gains (losses)	$100K—	$0—	$0—	$0—	$0—
Income tax expense	——	——	——	——	——
Net income	-$26.09M+85.3%	-$50.34M+74.9%	-$68.58M+68.3%	-$120.62M+40.3%	-$177.3M+8.4%
Net margin	-37.5%+531pp	-101.1%+544pp	-96.8%+4,042pp	-206.4%+5,344pp	-568%+7,809pp
Diluted earnings per share	-$0.07+86.3%	-$0.14+78.1%	-$0.19+74.7%	-$0.33+57.7%	-$0.51+38.6%
Basic earnings per share	-$0.07+86.3%	-$0.14+78.1%	-$0.19+74.7%	-$0.33+57.7%	-$0.51+38.6%
Weighted-average shares, diluted	1.5B+10.0%	1.5B+17.3%	1.4B+23.7%	1.4B+37.6%	1.4B+47.8%
Weighted-average shares, basic	1.5B+10.0%	1.5B+17.3%	1.4B+23.7%	1.4B+37.6%	1.4B+47.8%
Other expenses	$8.09M-35.1%	$8.34M-46.5%	$10.17M-40.7%	$12.57M-23.7%	$12.47M-23.2%
Accretion (Amortization) of Discounts and Premiums, Investments	$2.95M-68.1%	$3.71M-60.1%	$5.16M-45.2%	$7.13M—	$9.23M—
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	——	——	——	——	——
Share-based compensation expense related to employee stock plans	$12.55M+2.5%	$12.52M-7.3%	$11.22M-26.1%	$10.58M-35.0%	$12.24M-19.6%
Pre-tax stock-based compensation cost	$12.5M+2.5%	$12.4M-8.1%	$11.1M-27.0%	$10.5M-35.6%	$12.2M-19.7%
Amortization Of Financing Costs And Discounts	$1.98M+14.5%	$1.7M-7.9%	$1.61M-22.1%	$1.61M-29.5%	$1.73M-14.7%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	$4.2M—	-$3.33M—	$44.11M—	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$26.25M+85.2%	-$50.43M+74.8%	-$68.9M+68.1%	-$120.44M+40.4%	-$177.23M+8.4%
Defined Contribution Plan Cost Recognized	——	$800K-65.2%	$1.18M-42.0%	$1.55M-11.4%	$1.93M+30.5%
Effective tax rates	——	$0—	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——	——
Excess tax benefits associated with employee equity plans	——	$2.45M-34.8%	$2.78M-13.3%	$3.1M+17.4%	$3.43M+64.4%
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Write off of NOL carryovers due to expiration	——	——	——	——	——
Accrued financing costs	——	——	——	——	——
Goodwill impairment losses	——	$0—	$0—	$0—	$0—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$8.87M-71.2%	$14.34M-58.0%	$19.82M-47.3%	$25.29M-38.3%
Income Tax Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	-$10.57M+74.9%	-$18.45M+54.8%	-$26.33M+33.6%	-$34.21M+11.0%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$195K-57.0%	$259.75K-46.7%	$324.5K-37.6%	$389.25K-29.6%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$944K-77.7%	$1.77M-47.4%	$2.59M+4.7%	$3.42M+114%
Accounts payable and other current liabilities	——	——	——	——	$2.22M—
Increase (Decrease) in Accounts Receivable	——	——	——	-$437K—	$921K—
Increase (Decrease) in Inventories	$75K+124%	$50K+133%	-$478K-259%	-$417K-201%	-$313K-161%
Increase (Decrease) in Other Operating Assets	-$766K+34.6%	-$757K+34.3%	-$1.21M-104%	-$1.19M—	-$1.17M—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	-$3.69M—
Interest Paid, Excluding Capitalized Interest, Operating Activity	$6.84M-45.9%	$8.33M-35.5%	$9.77M-25.3%	$11.3M-14.8%	$12.63M+7.4%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$40.83M—	-$48.5M—	——	——	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$2.18M—	$113.02M—	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	——	——	——	——	-$167.43M+9.7%
Number of operating segments	——	10.0%	10.0%	10.0%	10.0%
Number of reportable segments	——	——	——	——	1.8—
Occupancy and Related Charges	$1.7M+13.3%	$1.6M+6.7%	$1.5M-6.3%	$1.5M-6.3%	$1.5M-6.3%
Operating Lease Payments	——	——	——	——	——
Unrealized gains (losses) on available-for-sale securities	-$156K—	-$90K—	——	——	——
Other Noncash Income (Expense)	$783K-58.8%	$1.74M+315%	$1.25M+163%	$352K+132%	$1.9M+171%
Other income, net (Note 6)	$6.23M-50.7%	$6.91M-43.8%	$8.46M-28.7%	$10.33M-9.6%	$12.63M+47.1%
Payment, Tax Withholding, Share-Based Payment Arrangement	——	——	——	——	——
Payments to Acquire Investments	$180.83M-14.1%	$139.84M-57.5%	$143.49M-52.6%	$159.39M-52.1%	$210.49M-44.3%
Proceeds from Issuance of Common Stock	——	——	——	——	-$88K—
Proceeds From Issuance Of Convertible Preferred Stock	$26.55M—	$0—	——	——	——
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$138K—	$73K—	——	——	——
Proceeds from disposition of marketable securities and other investments	$183M-47.3%	$252.86M-19.6%	$305.86M+6.8%	$323.41M+45.0%	$346.95M+68.7%
Gross realized gains (losses)	$100K—	$0—	$0—	$0—	$0—
Repayments of Debt	$53M—	$48M—	$45M—	$45M—	——
Royalty income	$168K+291%	$156K+95.0%	$24K-77.4%	$13K-88.3%	$43K-59.8%
Stock-based compensation	$12.55M+2.5%	$12.52M-7.3%	$11.22M-26.1%	$10.58M-35.0%	$12.24M-19.6%
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	——	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	——	$10.1M-67.2%	$15.28M-55.3%	$20.45M-45.6%	$25.63M-37.5%
EBIT	-$24.23M+86.3%	-$48.91M+75.2%	-$66.87M+68.3%	-$118.37M+39.9%	-$177.46M+4.6%
EBITDA	-$23.67M+86.6%	-$48.29M+75.4%	-$66.24M+68.5%	-$117.77M+40.1%	-$176.9M+4.6%
EBITDA	-$23.67M+86.6%	-$48.29M+75.4%	-$66.24M+68.5%	-$117.77M+40.1%	-$176.9M+4.6%
EBITDA margin	-34%+533pp	-97%+536pp	-93.5%+3,933pp	-201.6%+5,195pp	-566.7%+7,454pp
EBIT	-$24.23M+86.3%	-$48.91M+75.2%	-$66.87M+68.3%	-$118.37M+39.9%	-$177.46M+4.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Lexicon Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's revenue?: Lexicon Pharmaceuticals (LXRX) generated $69.6M in revenue over the trailing twelve months, up 123.1% year over year.
Is Lexicon Pharmaceuticals profitable?: Lexicon Pharmaceuticals is not currently profitable: it reported a net loss of $26.1M over the trailing twelve months, a -37.5% net margin.
What are Lexicon Pharmaceuticals's profit margins?: Gross margin is 99.5% and operating margin is -34.8%, with a -37.5% net margin.
What is Lexicon Pharmaceuticals's earnings per share?: Lexicon Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.07.
Where does Lexicon Pharmaceuticals's income statement data come from?: Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.